Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers

Study identification

• EU PAS number:
  EUPAS104305
• Study ID:
  104306
• Official title and acronym:
  Prevalence of primary and secondary arterial hypertension in children and treatment with angiotensin II receptor blockers
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  United Kingdom
• Study description:
  A descriptive study of the yearly prevalence of primary and secondary arterial hypertension in children and their treatment with angiotensin II receptor blockers
• Study status:
  Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned: 11/03/2022

Actual: 11/03/2022

Study start date

Planned: 11/03/2022

Actual: 11/03/2022

Date of final study report

Planned: 12/04/2022

Actual: 11/04/2022

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable